Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00HVP
|
||||
| Former ID |
DNC008417
|
||||
| Drug Name |
Riccardin C
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H24O4
|
||||
| Canonical SMILES |
C1CC2=C(C=CC(=C2)O)C3=C(C=C(CCC4=CC(=C(C=C4)O)OC5=CC=C1<br />C=C5)C=C3)O
|
||||
| InChI |
1S/C28H24O4/c29-22-9-13-24-21(17-22)8-3-18-4-10-23(11-5-18)32-28-16-20(7-14-26(28)30)2-1-19-6-12-25(24)27(31)15-19/h4-7,9-17,29-31H,1-3,8H2
|
||||
| InChIKey |
JMKSVONWZFVEAI-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Oxysterols receptor LXR-beta | Target Info | Inhibitor | [1] | |
| Oxysterols receptor LXR-alpha | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | PPAR signaling pathway | ||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Hepatitis C | |||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | Nuclear Receptor transcription pathway | ||||
| WikiPathways | SREBP signalling | ||||
| Nuclear ReceptorsWP299:Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Nuclear Receptors Meta-Pathway | |||||
| PPAR Alpha Pathway | |||||
| Liver X Receptor Pathway | |||||
| Adipogenesis | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. Epub 2008 Feb 29.Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.